Health Management And Vaccination 健康管理与疫苗





Jiayu WU 🔳

| | Title Internal Medicine Physician | Departm Internal Me Languag | |
|--|--|-----------------------------------|--|
| | Degrees MD | English French Mandarin | |
| | | Mandari | |

patients guidance in diet and exercise, guiding self-care and evaluation.

Dr. Wu received her Master degree of Medicine from Shanghai Jiaotong University in 2007. She completed her residency in internal medicine at Lariboisiere Hospital in Paris in 2006. In 2010, she participated in medical research of metabolic syndrome (MetS) and non alcoholic fatty liver disease (NAFLD) in Novel Hopital Civil in Strasbourg in France. She was later awarded a medical Doctor's degree in 2018 from Shanghai Jiaotong University.



nent edicine

ge



Dr. Wu has long been engaged in the clinical practice of common chronic diseases in internal medicine, especially in metabolic disease. She is also experienced in the management of critical patients with cardiovascular, respiratory and nervous system diseases, adapting therapy in consideration of coexisting and concurrent diseases, and giving

Personal Health Management

医者仁心一路相随 With You All The Way





Who needs proper medical care?

Everyone needs proper medical care!

And especially for those who have: -pre-existing disease -family history: cancer -high risks: -obesity

- -smoker
- -frequent alcohol intake
- -age and gender and race
- -high working load and stress









Shanghai United Family Hospital Executive Health Management Center




医者仁心一路相随 With You All The Way







Pre-existing checkup center



Pipeline operation

Person

No second year follow-up plan

Needs to seek extra-medical help

医者仁心一路相随 With You All The Way

UFH Health Management Center

NEW FRONTIER HEALTH



Personalized design based on physical condition

A face-to-face report interpretation, with analysis of the results, and prediction of a certain disease.

One-stop service

Personalized recommendation on a next year checkup

Problem solved in the same facility



Go home with a health management plan, instead of a checkup report.

Don't change your treatment or find an equivalent by yourself without medical advice.

医者仁心一路相随 With You All The Way





Do not delay a visit with doctor if you have any symptom.

2 Vaccines to prevent COVID-19 infection

医者仁心一路相随 With You All The Way





Background

✓ At the end of 2019, a novel coronavirus was identified as the cause of a cluster of pneumonia cases in Wuhan.

✓ In February 2020, the WHO named this disease COVID-19, which stands for coronavirus disease 2019.


 ✓ There is a lack of effective drugs
✓ So vaccines to prevent coronavirus infection are considered the most promising approach for curbing the pandemic.








| | Inactivated Vaccine | Vector Vaccine | recombinant protein nanoparticle vaccine | mRNA Vacci |
|--------------|--|--|--|---|
| Mechanism | virus cultured outside the body, and then inactivated, so that it is not toxic, but the "corpse" of these viruses. | Spike protein is the key to the novel coronavirus invasion of human cells. And ACE2 receptor acts as a door lock. | | mRNA or DNA are injected int body, and use human body ce S protein, stimulate the body antibodies. |
| | can still stimulate the human body to produce antibodies, so that immune cells remember the appearance of the virus. | Spike protein binds to ACE2 receptor and open the door to infect a human cell. | huge production of novel coronavirus most likely as antigen Spike protein | It is the equivalent of handing virus profile to the body's imn |
| | | Adenovirus as a vector, loaded into the S protein gene of novel Coronavirus, stimulate the human body to produce antibodies. | inject it into the human body, stimulate the human body to produce antibodies. | |
| Advantage | higher safety | Storage is more convenient | high specificity | produces not only IgG and IgN also cellular immune response |
| Disadvantage | | when a virus vector is used that the body has been exposed to, it may weaken the effectiveness of the immune response | difficult to find a good expression system | It's very unstable, so it require storage conditions. Pfizer vacc stored at -80° and Moderna a |
| | | | | it is unclear how long the imm with the vaccine will last, or w be side effects in the long terr |



| Name | CoronaVac | BBV152 | BBIBP-CorV | Gam-COVID-Vac (Sputnik V) | ChAdOx1 nCoV- 19/AZD1222 | Ad26.COV2.S | NVX-CoV2373 | BNT162b2 |
|---------------------------------------|-----------------------------|-----------------------------|-----------------------------|--|---|--|----------------------------|--|
| developer | SinoVac | Bharat Biotech | Sinopharm | Gamaleya Institute | AstraZeneca | Janssen/Johnson & Johnson | Novavax | Pfizer/BioNTech |
| Platform | Inactiated virus vaccine | Inactiated virus vaccine | Inactiated virus vaccine | Replication- incompetent adenovirus vector | Replication- incompetent adenovirus vector | Replication- incompetent adenovirus vector | Recombinant protein | mRNA |
| Doses | 2 doses | 2 doses | 2 doses | 2 doses | 2 doses | 1 dose | 2 doses | 2 doses |
| intended interval | 2 weeks apart | 4 weeks apart | 3 weeks apart | 3 weeks apart | 8 to 12 weeks apart (WHO) | / | 3 weeks apart | 3 weeks apart |
| Efficacy against original strain | 50% | 81% | 79% | 92% | 82% | 66% against moderate to severe COVID-19 | 96% | 95% |
| Efficacy against B1.351 SA variant | ? | ? | ? | ? | 10% | 57% | 55% | ? |
| Efficacy against B1.1.7 UK variant | ? | ? | ? | ? | ? | ? | 86% | ? |
| Storage requirements | Refrigerated (2 to 8°C) | Refrigerated (2 to 8°C) | Refrigerated (2 to 8°C) | Refrigerated (2 to 8°C) | Refrigerated (2 to 8°C) | Refrigerated (2 to 8°C) | Refrigerated (2 to 8°C) | freezer (–80 to –60°C) then freezer (–25 to –15°C) |
| Rare adverse effects | Unknown | Unknown | Unknown | Unknown | thrombocytopenia: Cerebral venous sinus thrombosis (169 of ≈ 34 million) | thrombocytopenia: Cerebral venous sinus thrombosis | Unknown | Anaphylaxis (approximately 5 per million) |

Last updated on 14/03/2021



Q&A about the vaccination

Q1: What are the adverse reactions?

- Local reactions: On the arm where you got the shot •Pain
- •Redness
- •Swelling

Systemic reactions: Throughout the rest of your body

- •Tiredness
- •Headache, muscle pain
- •Pruritus, rash
- •Fever and/or chills
- •Nausea
- •Scratchy sensations in the throat
- •Mild respiratory symptoms.





Q&A about the vaccination

Q2: How to deal with the adverse reaction?

Self observation, contact doctor.

Respiratory symptoms or systemic symptoms that occur after the first couple days following vaccination could be indicative of COVID-19 and warrant testing.

Q3:Do I need to check antibody after the injection?

Unless indicated to evaluate for suspected infection, there is no role for routine post-vaccination testing for COVID-19.

Specifically, serologic testing following vaccination to confirm an antibody response is not warranted. Many serologic tests will not detect the type of antibodies elicited by vaccination.





Vaccine, or not?

Always balance benefits and risks. Statistic doesn't matter individuals.

医者仁心一路相随 With You All The Way







Health Management Center

上海和睦家医院 Shanghai United Family Hospital 上海市平塘路699号 No 699, Ping Tang Road, Chang ning District, Shanghai



HMC Primary Care Manager

预约电话: 400 639 3900 Tel: +86 (21) 2216 3900